Scarica l'app Stockscreener
104.48
1.92%
1.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$102.51
Aprire:
$102.08
Volume 24 ore:
148.63K
Relative Volume:
1.29
Capitalizzazione di mercato:
$2.11B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
41.63
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
-4.49%
1M Prestazione:
+0.61%
6M Prestazione:
-13.83%
1 anno Prestazione:
+21.32%
Intervallo 1D:
$102.08
$107.15
Intervallo di 1 settimana:
$99.24
$109.20
Portata 52W:
$77.42
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
104.48 | 2.11B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus
Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus
Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations - Investing.com
Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth - TipRanks
Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Ligand: Q1 Earnings Snapshot - Huron Daily Tribune
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations By Investing.com - Investing.com UK
Ligand Pharmaceuticals Q1 Core Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell - marketscreener.com
Ligand (LGND) Upholds 2025 Financial Guidance | LGND Stock News - GuruFocus
Ligand Pharmaceuticals Reports Q1 Revenue of $45.3M, Beating Estimates; EPS Falls Short with $2.21 Loss - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves | LGND Stock News - GuruFocus
Ligand Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings Flash (LGND) Ligand Pharmaceuticals Posts Q1 Revenue $45.3M, vs. FactSet Est of $38.7M - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Mariner LLC Purchases Shares of 2,574 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Deal Watch: Lilly Looks To Creyon For Oligonucleotides - insights.citeline.com
Ligand to Participate in May Investor Conferences - Stock Titan
Ligand Pharmaceuticals (LGND) Projected to Post Earnings on Thursday - Defense World
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Wells Fargo & Company MN - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Sterling Capital Management LLC Has $59,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - American Banking and Market News
Ligand Q1 2025 Earnings Coming May 8: Key Financial Results and Business Updates Expected Pre-Market - Stock Titan
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 - Yahoo Finance
Ligand unit Pelthos to merge with Channel Therapeutics - MSN
LGND: Pelthos To Become Public Company - Yahoo Finance
North Carolina adds new public company — it's hiring - The Business Journals
Bank of Montreal Can Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
JPMorgan Chase & Co. Has $4.05 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Legal & General Group Plc Boosts Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of “Buy” by Analysts - Defense World
Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 - Seeking Alpha
Channel Therapeutics and Pelthos Therapeutics to Merge to Accelerate Launch of Zelsuvmi for Molluscum Contagiosum - Dermatology Times
Channel Therapeutics Sees Major Gains After Pharma Merger News - Finimize
Channel Therapeutics stock climbs on M&A deal (LGND:NASDAQ) - Seeking Alpha
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated - MSN
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated By Stocktwits - Investing.com India
Ligand’s Pelthos joins Channel - The Pharma Letter
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub - Nasdaq
Ligand Pharma Announces Merger to Enhance ZELSUVMI Sales - TipRanks
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel T - GuruFocus
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - The Manila Times
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | LGND Stock News - GuruFocus
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):